A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-related Fibrosis

Overview

Journal Obes Surg

Date 2010 Jun 10

PMID 20532833

Citations 50

Authors

Zobair M Younossi

Sandra Page

Nila Rafiq

Aybike Birerdinc

Maria Stepanova

Noreen Hossain

Arian Afendy

Zahra Younoszai

Zachary Goodman

Ancha Baranova

Affiliations

Soon will be listed here.

Abstract

Background: Patients with biopsy-proven NASH and especially those with fibrosis are at risk for progressive liver disease, emphasizing the clinical importance of developing non-invasive biomarkers for NASH and NASH-related fibrosis.

Aim: This study examines the performance of a new biomarker panel for NASH and NASH-related fibrosis with a combination of clinical and laboratory variables.

Methods: Enrolled patients had biopsy-proven NAFLD. Clinical data, laboratory data, and serum samples were collected at the time of biopsy. Fasting serum was assayed for adiponectin, resistin, glucose, M30, M65, Tissue inhibitor of metalloproteinases-1 (Timp-1), ProCollagen 3 N-terminal peptide (PIIINP), and hyaluronic acid (HA). Regression models predictive of NASH, NASH-related fibrosis, and NASH-related advanced fibrosis were designed and cross-validated.

Results: Of the 79 enrolled NAFLD patients, 40 had biopsy-proven NASH and 39 had non-NASH NAFLD. Clinical and laboratory data were from this cohort were used to develop a NAFLD Diagnostic Panel that includes three models (models for NASH, NASH-related fibrosis, and NASH-related advanced fibrosis). The model for predicting NASH includes diabetes, gender, BMI, triglycerides, M30 (apoptosis), and M65-M30 (necrosis) [AUC: 0.81, 95% CI, 0.70-0.89, 300 p value <9E 301 (-06)]. The NASH-related fibrosis prediction model includes the same predictors [AUC: 0.80, 95% CI 0.68-0.88, 307 p value <0.00014]. Finally, the NASH-related advanced fibrosis model includes type 2 diabetes, serum triglycerides, Timp-1, and AST [AUC: 0.81, 95% CI, 0.70-0.89; p value, 0.000062].

Conclusions: This NAFLD Diagnostic Panel based on a clinical and laboratory data has good performance characteristics and is easy to use. This biomarker panel could become useful in the management of patients with NAFLD.

Citing Articles

Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease.

Gilca-Blanariu G, Budur D, Mitrica D, Gologan E, Timofte O, Balan G Metabolites. 2023; 13(11).

PMID: 37999211 PMC: 10672868. DOI: 10.3390/metabo13111115.

The Effect of Laparoscopic Sleeve Gastrectomy and Gastric Bypass Surgery on Non-Alcoholic Steatohepatitis in Iranian Patients with Obesity.

Elyasinia F, Jalali S, Zarini S, Sadeghian E, Sorush A, Pirouz A Middle East J Dig Dis. 2023; 13(3):200-207.

PMID: 36606220 PMC: 9489465. DOI: 10.34172/mejdd.2021.226.

Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?.

Francisco V, Sanz M, Real J, Marques P, Capuozzo M, Ait Eldjoudi D Biology (Basel). 2022; 11(8).

PMID: 36009862 PMC: 9405285. DOI: 10.3390/biology11081237.

Non-invasive tests of non-alcoholic fatty liver disease.

Li G, Zhang X, Lin H, Liang L, Wong G, Wong V Chin Med J (Engl). 2022; 135(5):532-546.

PMID: 35089884 PMC: 8920457. DOI: 10.1097/CM9.0000000000002027.

acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.

Wu X, Zheng K, Boursier J, Chan W, Yilmaz Y, Romero-Gomez M EClinicalMedicine. 2021; 41:101145.

PMID: 34646997 PMC: 8495106. DOI: 10.1016/j.eclinm.2021.101145.

References

Younossi Z, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born T . A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005; 42(3):665-74. DOI: 10.1002/hep.20838. View

Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M . Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther. 2007; 25(2):207-18. DOI: 10.1111/j.1365-2036.2006.03182.x. View

Bondini S, Kleiner D, Goodman Z, Gramlich T, Younossi Z . Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis. 2007; 11(1):17-23, vii. DOI: 10.1016/j.cld.2007.02.002. View

Cadranel J, Rufat P, Degos F . Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000; 32(3):477-81. DOI: 10.1053/jhep.2000.16602. View

Rosenberg W, Voelker M, Thiel R, Becka M, Burt A, Schuppan D . Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004; 127(6):1704-13. DOI: 10.1053/j.gastro.2004.08.052. View

Baranova A, Liotta L, Petricoin E, Younossi Z . The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis. 2007; 11(1):209-20, xi. DOI: 10.1016/j.cld.2007.02.003. View

Baranova A, Younossi Z . The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology. 2008; 47(2):373-5. DOI: 10.1002/hep.22140. View

Shimizu I, Kohno N, Tamaki K, Shono M, Huang H, He J . Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol. 2007; 13(32):4295-305. PMC: 4250853. DOI: 10.3748/wjg.v13.i32.4295. View

Nugent C, Younossi Z . Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007; 4(8):432-41. DOI: 10.1038/ncpgasthep0879. View

10.

Edmison J, McCullough A . Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis. 2007; 11(1):75-104, ix. DOI: 10.1016/j.cld.2007.02.011. View

11.

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R . Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37(4):917-23. DOI: 10.1053/jhep.2003.50161. View

12.

Rafiq N, Younossi Z . Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009; 13(2):249-66. DOI: 10.1016/j.cld.2009.02.009. View

13.

Wai C, Greenson J, Fontana R, Kalbfleisch J, Marrero J, Conjeevaram H . A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2):518-26. DOI: 10.1053/jhep.2003.50346. View

14.

Itagaki T, Shimizu I, Cheng X, Yuan Y, Oshio A, Tamaki K . Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. Gut. 2005; 54(12):1782-9. PMC: 1774809. DOI: 10.1136/gut.2005.053278. View

15.

London R, George J . Pathogenesis of NASH: animal models. Clin Liver Dis. 2007; 11(1):55-74, viii. DOI: 10.1016/j.cld.2007.02.010. View

16.

Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N . Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7(11):1224-9, 1229.e1-2. DOI: 10.1016/j.cgh.2009.06.007. View

17.

Miele L, Forgione A, Gasbarrini G, Grieco A . Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007; 149(3):114-25. DOI: 10.1016/j.trsl.2006.11.011. View

18.

Lazo M, Clark J . The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28(4):339-50. DOI: 10.1055/s-0028-1091978. View

19.

Younossi Z, Diehl A, Ong J . Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002; 35(4):746-52. DOI: 10.1053/jhep.2002.32483. View

20.

Charatcharoenwitthaya P, Lindor K . Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis. 2007; 11(1):37-54, viii. DOI: 10.1016/j.cld.2007.02.014. View